Adjuvant Stereotactic Fractionated Radiotherapy to the Resection Cavity in Recurrent Glioblastoma (GlioCave/NOA17)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02715297|
Recruitment Status : Recruiting
First Posted : March 22, 2016
Last Update Posted : September 20, 2018
|Condition or disease||Intervention/treatment||Phase|
|Glioblastoma||Radiation: SRT to the resection cavity||Phase 2|
The treatment of recurrent glioblastoma is, beside of its abundance in clinical practice, still under discussion. Patients presenting with recurrent disease are therefore treated within individual concepts, largely based on small prospective trials, retrospective evaluations or case reports. Therefore, the treatment ranges from best supportive care over primary systemic treatments towards local therapies such as radiotherapy or surgical resection. Even if there might be a large selection bias, local therapies with or without concomitant or adjuvant chemotherapy seem to promise the largest prognostic benefit. Whether the combination of surgical resection and adjuvant radiotherapy improves survival, as it does within the primary situation, is unknown.
The result of surgical resection might have an impact as well. Several case reports, retrospective evaluations and prospective studies have also included patients with remaining gross tumor after maximum save resection. In these trials, radiotherapy was associated with improvements in progression free as well as overall survival. Therefore, the influence of neuroimaging on prognosis is currently evaluated within the GLIA-A trial. Furthermore, stereotactic radiotherapy with or without an experimental systemic therapy is currently investigated within another multicenter randomized trial (NOA-12).
Whether patients might benefit from a postoperative radiotherapy of the resection cavity after complete extirpation of all macroscopic tumor is key question of this protocol.
To answer this question, the considered standard of care after complete resection, namely observation with or without adjuvant systemic therapy, will be compared to a postoperative normofractionated stereotactic radiotherapy towards the resection cavity within an open label, randomized trial. The prescribed total dose will be 46 Gy in 2 Gy fractions of 36 Gy in 3 Gy fractions depending on the treatment volume.
Concerning safety, side effects will be monitored prospectively. Safety parameters will be compared between both arms of the study. Furthermore, measures for quality of life, neurocognitive function as well as neuroimaging features will be evaluated prospectively.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||162 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Adjuvant Stereotactic Fractionated Radiotherapy to the Resection Cavity in Recurrent Glioblastoma|
|Study Start Date :||February 2016|
|Estimated Primary Completion Date :||March 2020|
|Estimated Study Completion Date :||March 2020|
Experimental: Arm A: SRT to the resection cavity
Postoperative stereotactic fractionated radiotherapy (SRT) to the resection cavity to a Total Dose of 46 Gy, 2 Gy single dose, or 36 Gy in 3 Gy single dose 5 fractions/week, depending on the volume and location of the treatment region.
Radiation: SRT to the resection cavity
46 Gy total dose will be delivered in 2 Gy per fraction, or 36 Gy delivered in 3 Gy per fraction, 5 fractions within 1 week. Doses will have to cover 95% of the PTV with the prescribed dose. The clinical target volume (CTV) will be defined as the resection cavity of the recurrent glioblastoma plus a margin of 5mm. A CTV to PTV margin of 1 to 3mm will be added according to technique used for immobilisation.
No Intervention: Arm B: Observation
Observation without adjuvant radiotherapy.
- Progression free survival (PFS) at 12 months [ Time Frame: 1 year ]
PFS will be defined according to the MacDonald and RANO-Criteria; Complete remission: Remission of all contrast-enhanced lesions on CT or MRI without worsening of neurologic status
Partial remission: at least 50% remission of the contrast-enhancing lesions on CT or MRI without increase in steroid medication and without worsening of the neurologic status
Stable disease: Remission of the solid tumor/contrast-enhancing lesion on CT or MRI of less than 50% or progression of the solid tumor/contrast-enhancing lesion on CT or MRI of less than 25%, without increase in steroid medication of worsening of the neurologic status
Progression: Increase in solid tumor/contrast-enhancing lesion of 25% or more or development of a new lesion
- Overall survival [ Time Frame: 1 year ]Patients will be followed up until death or for at least 1 year. Living patients will be censored according to the date of their last visit.
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.03 [ Time Frame: 1 year ]Safety and tolerability will be assessed by quality and quantity according to the International Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 for toxicity and adverse event reporting. Safety and toxicity of the study treatment will be evaluated by clinical neurological examination as well as neuro-imaging studies (MRI or CT).
- Quality of Life questionnaire [ Time Frame: 1 year ]The EORTC QLQ-C30 version 3.0 questionnaire will be used to monitor for Quality of Life continuously throughout the treatment course as well as during follow up.
- Neurocognitive function [ Time Frame: 1 year ]Neurocognitive function will be assessed at randomisation, at 6 months and at 12 months after randomization. A battery containing of 3 tests will be used. For assessment of learning, early and intermediate recall, the German version of the California Verbal Learning Test (CVLT) as well as the Regensburger Wortflüssigkeits-Test (RWT) will be used. Cognitive flexibility, speed as well as attention will be tested by the Trail-Making-Test. The tests at 6 and at 12 months will be compared to the result of the baseline measure as well as to each other.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02715297
|Contact: Stephanie E. Combs, Prof. Dr.||0049 email@example.com|
|Contact: Christoph Straube, Dr.||0049 firstname.lastname@example.org|
|Dept. Radiation Oncology||Recruiting|
|Munich, Bavaria, Germany, 81675|
|Contact: Stephanie E. Combs, Prof. Dr. 089 4140 4501 email@example.com|
|Contact: Christoph Straube, Dr.|
|Principal Investigator:||Stephanie E. Combs, Prof. Dr.||Klinik für RadioOnkologie und Strahlentherapie|